Skip to main content
SpringerLink
Log in

Internationale Empfehlungen

Therapie der Psoriasisarthritis

  • Zertifizierte Fortbildung
  • Therapie der Psoriasisarthritis
  • Published:
hautnah dermatologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1:
Abb. 2:

Literatur

  1. Reich K et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009; 160: 1040-7

  2. Helliwell PS etl al. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis. 2005; 64: ii3-8

  3. Coates LC et al. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res. 2010; 62: 965-9

  4. Coates LC et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015; 386: 2489-98

  5. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF). Therapieleitlinie der Psoriasis vulgaris. 2011; www.AWMF.org. Zugegriffen: 2020

  6. Nast A et al. S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1. J Dtsch Dermatol Ges. 2018; 16: 645-69

  7. Gossec L et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016; 75: 499-510

  8. Coates LC et al. New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation. Br J Dermatol. 2016; 174: 1174-8

  9. Behrens F et al. Psoriatic arthritis: Overview of drug therapy options and administration characteristics. Hautarzt. 2017; 68: 153-69

  10. Eder L et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford), 2010; 49: 1367-73

  11. Kingsley GH et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012; 51: 1368-77

  12. Baranauskaite A et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012; 71: 541-8

  13. Behrens F et al. Does concomitant Methotrexate with Adalimumab influence treatment outcomes in patients with Psoriatic arthritis? Data from a large observational study. J Rheumatol. 2016; 43: 632-9

  14. Mease PJ et al. Etanercept and Methotrexate as Monotherapy or in combination for Psoriatic arthritis: primary results from a randomized, controlled phase 3 trial. Arthritis Rheumatol. 2019; 71: 1112-24.

  15. Fagerli KM et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis. 2014; 73: 132-7

  16. Behrens F et al. Update 2011: leflunomide in rheumatoid arthritis -strengths and weaknesses. Curr Opin Rheumatol. 2011; 23: 282-7

  17. Kaltwasser et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, doubleblind, randomized, placebocontrolled clinical trial. Arthritis Rheum. 2004; 50: 1939-50

  18. Nash P et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology. 2006; 212: 238-49

  19. Ho VC et al. Intermittent short courses of cyclosporin for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol. 1999; 141: 283-91

  20. Acosta Felquer ML et al (2014) Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review. J Rheumatol 41: 2277-85

  21. Clegg DO et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study. Arthritis Rheum. 1996; 39: 2013-20

  22. Cutolo M et al .A phase III, randomized, controlled trial of Apremilast in patients with Psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016; 43: 1724-34

  23. Gladman D et al. Tofacitinib for Psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017; 377: 1525-36

  24. Yoo DH et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013; 72: 1613-20

  25. Zweegers J et al. Comparison of the one and 5 years effectiveness of adalimumab, etanercept and ustekinumab in psoriasis patients in daily clinical practice: results from the prospective bioCAPTURE registry. Br J Dermatol. 2017; 176: 1001-9

  26. Leonardi CL Y et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008; 371: 1665-74

  27. Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo- controlled trial (PHOENIX 2). Lancet. 2008; 371: 1675-84

  28. McInnes IB et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013; 382: 780-9

  29. Ritchlin C et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6 month and 1 year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014; 73: 990-9

  30. Araujo EG et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2019; 48: 632-7

  31. Mease PJ et al. Secukinumab inhibition of Interleukin-17A in patients with Psoriatic arthritis. N Engl J Med. 2015; 373: 1329-39

  32. Langley RG et al. Secukinumab in plaque psoriasis - results of two phase 3 trials. N Engl J Med. 2014; 371: 326-38

  33. Krueger JG et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012; 130: 145-54

  34. Griffiths CE et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER 2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015; 386: 541-51

  35. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015; 27: 127-33

  36. Mease PJ et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014; 370: 2295-306

  37. Papp K et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014; 71: 1183-90.e3

  38. Papp K CE et al. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology. 2015; 72: 436-9e1

  39. Blauvelt A et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017; 76: 405-17

  40. Coates LC et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016; 68: 1060-71

Download references

Author information

Authors and Affiliations

  1. Goethe-Universität Frankfurt, Abt. Rheumatologie, Theodor-Stern-Kai 7, 60596, Frankfurt/Main, Germany

    Frank Behrens &  Michaela Köhm

Authors
  1. Frank Behrens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michaela Köhm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank Behrens.

Ethics declarations

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: M. Köhm: Forschungsunterstützung von Janssen, Pfizer, AbbVie; Vortrags-/ Beraterhonorar: Janssen, Pfizer, Celgene. F. Behrens: Forschungsunterstützung: AbbVie, Pfizer, Roche, Chugai,Novartis; Vortrags-/Beraterhonorar: AbbVie,Pfizer, Roche, Chugai, UCB, BMS, Celgene, MSD, Novartis, Biotest, Janssen, Genzyme, Lilly, Sandoz. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME- Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Behrens, F., Köhm, M. Therapie der Psoriasisarthritis. hautnah dermatologie 36, 44–53 (2020). https://doi.org/10.1007/s15012-020-4032-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15012-020-4032-2

Search

Navigation